Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis-Reference-Cited by-同舟云学术

Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis

Published:2002-11 Issue:9 Volume:74 Page:1207-1210
ISSN:0041-1337
Container-title:Transplantation
language:en
Short-container-title:Transplantation

Author:

Sawada Tokihiko,Fuchinoue Shohei,Teraoka Satoshi

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Transplantation

Reference13 articles.

1. LONG-TERM RESULTS OF ABO-INCOMPATIBLE LIVING KIDNEY TRANSPLANTATION

2. ABO-incompatibility in solid organ transplantation

3. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients

4. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia

Cited by 120 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancement in preoperative desensitization therapy for ABO incompatible kidney transplantation recipients;Transplant Immunology;2023-10

2. Therapeutic apheresis in kidney diseases: an updated review;Renal Failure;2022-06-19

3. Role of double-filtration plasmapheresis in ABO- and human leukocyte antigen-incompatible kidney transplant;Global Journal of Transfusion Medicine;2022

4. Desensitization Regimen Consisting of High-Dose Intravenous Immunoglobulin, Plasmapheresis, and Rituximab (an Anti-CD20 Antibody), Without Eculizumab and/or Bortezomib, in 41 Highly Sensitized Kidney Transplant Recipients;Experimental and Clinical Transplantation;2021-10

5. Impact of rituximab on the T-cell flow cytometric crossmatch;Transplant Immunology;2021-02